|
PALM007
|
Research Initiative
|
CDC
|
NIAID
|
Clinical trial of safety and efficacy of tecovirimat to treat Mpox in adults and children in DRC
|
|
Pandemic Influenza Translational Research and novel universal countermeasure development
|
Research Initiative
|
FDA
|
OD/OIR, NIAID
|
Pandemic Influenza Translational Research and novel universal countermeasure development
|
|
Pandemic Response Team
|
Other
|
ASPR, CDC
|
NIAID
|
Ongoing work and collaboration since the COVID-19 pandemic for COVID-19 vaccines allocation approvals for the use in NIH clinical trials and preclinical studies
|
|
PAR 22-049 'Integrating Biospecimen Science Approaches into Clinical Assay Development' Steering Committee Collaboration
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI
|
As part of a U01 grants program/network, the Steering Committee provides an opportunity to improve the quality of funded research and potentially amplify the impact of the grants program through collaborative activities. The Steering Committee collaboratively reviews research progress and develops collaborative activities that may include, among other activities, joint research projects, and advocates for the sharing of data and biospecimens within the network.
|
|
Pathogen Detection Project and Interagency Collaboration on Genomics for Food and Feed Safety (Gen-FS)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NLM
|
The Pathogen Detection Project is a multi-agency collaboration that combines data from pathogen outbreaks with other information to determine the major source of contamination. Collaborating agencies include NLM, the Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), USDA-Food Safety and Inspection Service, and Public Health England. The US agencies formalized their collaboration in a charter document (Interagency Collaboration on Genomics for Food and Feed Safety (Gen-FS)) that includes coordinating activities on antimicrobial resistance.
|
|
Pathophysiological Actions of Anthrax Virulence Determinants
|
Research Initiative
|
FDA
|
NIAID
|
Pathophysiological Actions of Anthrax Virulence Determinants
|
|
Pathways to Prevention (P2P) Workshop Program
|
Meeting/ Workshop
|
AHRQ, CDC, ONC, OASH, ASPE, SAMHSA, HRSA, IHS
|
OD/DPCPSI/ODP, NCATS, NHLBI, NCI, NIMH, NIMHD, NICHD, NINDS, NIA, OD/DPCPSI/ORWH
|
The Pathways to Prevention (P2P) program is a workshop series hosted by the Office of Disease Prevention (ODP) to identify research gaps in a selected scientific area, identify methodological and scientific weaknesses in that scientific area, suggest research needs, and move the field forward through an unbiased, evidence-based assessment of a complex public health issue. P2P workshops are designed for topics that have incomplete or underdeveloped research and for which there is a need for a systematic evidence review that synthesizes the published literature. After each workshop, ODP also organizes a meeting of all Federal Partners who have an interest in or activities related to the workshop topic to discuss ways that the Federal Partners might collaborate to implement workshop recommendations.
|
|
PCC Technical Working Group on PFAS
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, ATSDR
|
NIEHS
|
Technical coordination on toxicology, exposure, analysis, mitigation of PFAS
|
|
PCORTF Frailty Functional Disabilities Project Working Group
|
Research Initiative
|
ASPE, AHRQ, CDC, CMS
|
NIA
|
Validate and Expand Claims-Based Algorithms, Identifying Patients with Frailty and Functional Disabilities across Payer and Patient Populations
|
|
Pediatric COVID-19/MIS-C Interagency Team
|
Committee, Work group, Advisory group, or Task Force
|
FDA, CDC, ASPR
|
NICHD, NHLBI, NIAID
|
This group was initially focused on MIS-C and coordinating MIS-C efforts across CDC, FDA and NIH. The case definition was finalized by CDC colleagues; the mission of this group remains the same, which is to coordinate surveillance and research in human services programmatic development across HHS; group shifted to focusing on both pediatric COVID more broadly as well as MIS-C.
|